

# Christoph U Correll

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/10760953/christoph-u-correll-publications-by-year.pdf>

**Version:** 2024-04-29

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

255  
papers

21,097  
citations

74  
h-index

141  
g-index

264  
ext. papers

26,297  
ext. citations

6.2  
avg, IF

7.15  
L-index

| #   | Paper   | IF   | Citations |
|-----|---|------|-----------|
| 255 | The post COVID-19 healthcare landscape and the use of long-acting injectable antipsychotics for individuals with schizophrenia and bipolar I disorder: the importance of an integrated collaborative-care approach.. <i>BMC Psychiatry</i> , <b>2022</b> , 22, 32 | 4.2  | 1         |
| 254 | Long-term safety and effectiveness of open-label lurasidone in antipsychotic-Naïve versus previously treated adolescents with Schizophrenia: A post-hoc analysis.. <i>Schizophrenia Research</i> , <b>2022</b> , 240, 205-213                                     | 3.6  | 1         |
| 253 | Treatment Approaches for First Episode and Early-Phase Schizophrenia in Adolescents and Young Adults: A Delphi Consensus Report from Europe.. <i>Neuropsychiatric Disease and Treatment</i> , <b>2022</b> , 18, 201-219   | 3.1  | 1         |
| 252 | Systematic literature review of schizophrenia clinical practice guidelines on acute and maintenance management with antipsychotics.. <i>NPJ Schizophrenia</i> , <b>2022</b> , 8, 5  | 5.5  | 4         |
| 251 | Psychological and Psychopharmacological Interventions in Psychocardiology.. <i>Frontiers in Psychiatry</i> , <b>2022</b> , 13, 831359   | 5    | 2         |
| 250 | Amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill patients with schizophrenia in Germany (COMBINE): a double-blind randomised controlled trial.. <i>Lancet Psychiatry</i> , <b>2022</b> , 9, 291-306                        | 23.3 | 2         |
| 249 | Half a century of research on antipsychotics and schizophrenia: A scientometric study of hotspots, nodes, bursts, and trends.. <i>Neuroscience and Biobehavioral Reviews</i> , <b>2022</b> , 136, 104608  | 9    | 5         |
| 248 | Short-term Efficacy and Safety of Lurasidone Versus Placebo in Antipsychotic-Naïve vs. Previously Treated Adolescents with an Acute Exacerbation of Schizophrenia.. <i>European Psychiatry</i> , <b>2022</b> , 1-35   | 6    | 1         |
| 247 | Temporal trends in associations between severe mental illness and risk of cardiovascular disease: A systematic review and meta-analysis.. <i>PLoS Medicine</i> , <b>2022</b> , 19, e1003960   | 11.6 | 5         |
| 246 | Associations between mental and physical conditions in children and adolescents: An umbrella review.. <i>Neuroscience and Biobehavioral Reviews</i> , <b>2022</b> , 137, 104662   | 9    | 4         |
| 245 | Mortality in people with schizophrenia: a systematic review and meta-analysis of relative risk and aggravating or attenuating factors.. <i>World Psychiatry</i> , <b>2022</b> , 21, 248-271   | 14.4 | 8         |
| 244 | Oral and long-acting antipsychotics for relapse prevention in schizophrenia-spectrum disorders: a network meta-analysis of 92 randomized trials including 22,645 participants.. <i>World Psychiatry</i> , <b>2022</b> , 21, 295-307                               | 14.4 | 2         |
| 243 | The transition from adolescence to adulthood in patients with schizophrenia: Challenges, opportunities and recommendations.. <i>European Neuropsychopharmacology</i> , <b>2022</b> , 59, 45-55  | 1.2  | 0         |
| 242 | Long-term efficacy and safety of once-monthly Risperidone ISM <sup>®</sup> in the treatment of schizophrenia: Results from a 12-month open-label extension study. <i>Schizophrenia Research</i> , <b>2021</b> , 239, 83-91  | 3.6  | 0         |
| 241 | Controversies Surrounding the Use of Long-Acting Injectable Antipsychotic Medications for the Treatment of Patients with Schizophrenia. <i>CNS Drugs</i> , <b>2021</b> , 35, 1189-1205  | 6.7  | 3         |
| 240 | Longitudinal Course of Depressive, Anxiety, and Posttraumatic Stress Disorder Symptoms After Heart Surgery: A Meta-Analysis of 94 Studies. <i>Psychosomatic Medicine</i> , <b>2021</b> , 83, 85-93  | 3.7  | 4         |
| 239 | How can we improve antidepressant adherence in the management of depression? A targeted review and 10 clinical recommendations. <i>Revista Brasileira De Psiquiatria</i> , <b>2021</b> , 43, 189-202  | 2.6  | 9         |

|     |   |      |                |
|-----|---|------|----------------|
| 238 | Association of Low-Dose Quetiapine and Diabetes. <i>JAMA Network Open</i> , <b>2021</b> , 4, e213209  | 10.4 | 1              |
| 237 | Preventive psychiatry: a blueprint for improving the mental health of young people. <i>World Psychiatry</i> , <b>2021</b> , 20, 200-221   | 14.4 | 4 <sup>8</sup> |
| 236 | Socio-economic position as a moderator of cardiometabolic outcomes in patients receiving psychotropic treatment associated with weight gain: results from a prospective 12-month inception cohort study and a large population-based cohort. <i>Translational Psychiatry</i> , <b>2021</b> , 11, 360          | 8.6  | 1              |
| 235 | Dietary Consumption Among Youth with Antipsychotic-Induced Weight Gain and Changes Following Healthy Lifestyle Education. <i>Journal of Child and Adolescent Psychopharmacology</i> , <b>2021</b> , 31, 364-375   | 2.9  | 1              |
| 234 | The Collaborative Outcomes study on Health and Functioning during Infection Times in Adults (COH-FIT-Adults): Design and methods of an international online survey targeting physical and mental health effects of the COVID-19 pandemic.. <i>Journal of Affective Disorders</i> , <b>2021</b> , 299, 393-393 | 6.6  | 2              |
| 233 | Oxidative stress parameters and antioxidants in patients with bipolar disorder: Results from a meta-analysis comparing patients, including stratification by polarity and euthymic status, with healthy controls. <i>Bipolar Disorders</i> , <b>2021</b> , 23, 117-129  | 3.8  | 11             |
| 232 | Mortality After the First Diagnosis of Schizophrenia-Spectrum Disorders: A Population-based Retrospective Cohort Study. <i>Schizophrenia Bulletin</i> , <b>2021</b> , 47, 864-874   | 1.3  | 5              |
| 231 | Does Switching Antipsychotics Ameliorate Weight Gain in Patients With Severe Mental Illness? A Systematic Review and Meta-analysis. <i>Schizophrenia Bulletin</i> , <b>2021</b> , 47, 948-958   | 1.3  | 6              |
| 230 | Safety and tolerability of lumateperone 42mg: An open-label antipsychotic switch study in outpatients with stable schizophrenia. <i>Schizophrenia Research</i> , <b>2021</b> , 228, 198-205   | 3.6  | 7              |
| 229 | Antipsychotics Use Is Associated With Greater Adherence to Cardiometabolic Medications in Patients With Schizophrenia: Results From a Nationwide, Within-subject Design Study. <i>Schizophrenia Bulletin</i> , <b>2021</b> ,  | 1.3  | 5              |
| 228 | Outcomes associated with different vaccines in individuals with bipolar disorder and impact on the current COVID-19 pandemic- a systematic review. <i>European Neuropsychopharmacology</i> , <b>2021</b> , 54, 90-90  | 1.2  | 1              |
| 227 | Risk and protective factors for mental disorders beyond genetics: an evidence-based atlas. <i>World Psychiatry</i> , <b>2021</b> , 20, 417-436  | 14.4 | 21             |
| 226 | The Impact of Pharmacological and Non-Pharmacological Interventions to Improve Physical Health Outcomes in People With Schizophrenia: A Meta-Review of Meta-Analyses of Randomized Controlled Trials. <i>Focus (American Psychiatric Publishing)</i> , <b>2021</b> , 19, 116-128                              | 1.1  | 3              |
| 225 | What are the physical and mental health implications of duration of untreated psychosis?. <i>European Psychiatry</i> , <b>2021</b> , 64, e46  | 6    |                |
| 224 | Safety and effectiveness of ulotaront (SEP-363856) in schizophrenia: results of a 6-month, open-label extension study. <i>NPJ Schizophrenia</i> , <b>2021</b> , 7, 63   | 5.5  | 7              |
| 223 | An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels.. <i>Pharmacopsychiatry</i> , <b>2021</b> , 55,   | 2    | 11             |
| 222 | Consensus statement on the use of clozapine during the COVID-19 pandemic. <i>Journal of Psychiatry and Neuroscience</i> , <b>2020</b> , 45, 222-223   | 4.5  | 5 <sup>0</sup> |
| 221 | Clozapine Combination and Augmentation Strategies in Patients With Schizophrenia -Recommendations From an International Expert Survey Among the Treatment Response and Resistance in Psychosis (TRRIP) Working Group. <i>Schizophrenia Bulletin</i> , <b>2020</b> , 46, 1459-1470                             | 1.3  | 16             |

|     |  |      |     |
|-----|--|------|-----|
| 220 | Clinical validation of the self-reported Glasgow Antipsychotic Side-effect Scale using the clinician-rated UKU side-effect scale as gold standard reference. <i>Journal of Psychopharmacology</i> , <b>2020</b> , 34, 820-828  | 4.6  | 4   |
| 219 | The report of the joint WPA/CINP workgroup on the use and usefulness of antipsychotic medication in the treatment of schizophrenia. <i>CNS Spectrums</i> , <b>2020</b> , 1-25  | 1.8  | 6   |
| 218 | A symptom combination predicting treatment-resistant schizophrenia - A strategy for real-world clinical practice. <i>Schizophrenia Research</i> , <b>2020</b> , 218, 195-200   | 3.6  | 4   |
| 217 | Frequency and Correlates of Acute Dystonic Reactions After Antipsychotic Initiation in 441 Children and Adolescents. <i>Journal of Child and Adolescent Psychopharmacology</i> , <b>2020</b> , 30, 366-375   | 2.9  | 1   |
| 216 | Safety of Psychotropic Medications in People With COVID-19: Evidence Review and Practical Recommendations. <i>Focus (American Psychiatric Publishing)</i> , <b>2020</b> , 18, 466-481  | 1.1  | 2   |
| 215 | The Neurobiology of Treatment-Resistant Schizophrenia: Paths to Antipsychotic Resistance and A Roadmap for Future Research. <i>Focus (American Psychiatric Publishing)</i> , <b>2020</b> , 18, 456-465   | 1.1  | 4   |
| 214 | Diagnostic stability in children and adolescents with bipolar disorder, a nationwide register-based study. <i>International Journal of Bipolar Disorders</i> , <b>2020</b> , 8, 14   | 5.4  | 3   |
| 213 | Cariprazine in the management of negative symptoms of schizophrenia: state of the art and future perspectives. <i>Future Neurology</i> , <b>2020</b> , 15, FNL52   | 1.5  | 3   |
| 212 | Rejoinder to rejoinder to commentary. <i>Psychological Medicine</i> , <b>2020</b> , 50, 2812-2813  | 6.9  |     |
| 211 | A randomized double-blind controlled trial to assess the benefits of amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill schizophrenia patients (COMBINE): methods and design. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , <b>2020</b> , 270, 83-94 | 5.1  | 3   |
| 210 | 20-year follow-up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20). <i>World Psychiatry</i> , <b>2020</b> , 19, 61-68   | 14.4 | 107 |
| 209 | The neurobiology of treatment-resistant schizophrenia: paths to antipsychotic resistance and a roadmap for future research. <i>NPJ Schizophrenia</i> , <b>2020</b> , 6, 1  | 5.5  | 79  |
| 208 | Efficacy and Safety of Lumateperone for Treatment of Schizophrenia: A Randomized Clinical Trial. <i>JAMA Psychiatry</i> , <b>2020</b> , 77, 349-358  | 14.5 | 108 |
| 207 | Metformin add-on vs. antipsychotic switch vs. continued antipsychotic treatment plus healthy lifestyle education in overweight or obese youth with severe mental illness: results from the IMPACT trial. <i>World Psychiatry</i> , <b>2020</b> , 19, 69-80   | 14.4 | 34  |
| 206 | Predictors of psychosis breakthrough during 24 months of long-acting antipsychotic maintenance treatment in first episode schizophrenia. <i>Schizophrenia Research</i> , <b>2020</b> , 225, 55-62  | 3.6  | 12  |
| 205 | Disparities in cancer screening in people with mental illness across the world versus the general population: prevalence and comparative meta-analysis including 4 717 839 people. <i>Lancet Psychiatry</i> , <b>2020</b> , 7, 52-63   | 23.3 | 45  |
| 204 | Leptin Serum Levels are Associated With GLP-1 Receptor Agonist-Mediated Effects on Glucose Metabolism in Clozapine- or Olanzapine-Treated, Prediabetic, Schizophrenia Patients. <i>Schizophrenia Bulletin Open</i> , <b>2020</b> , 1,  | 2.2  | 1   |
| 203 | Medical management of eating disorders: an update. <i>Current Opinion in Psychiatry</i> , <b>2020</b> , 33, 542-553  | 4.9  | 4   |

|     |  |      |     |
|-----|--|------|-----|
| 202 | Psychosis relapse during treatment with long-acting injectable antipsychotics in individuals with schizophrenia-spectrum disorders: an individual participant data meta-analysis. <i>Lancet Psychiatry, the</i> , <b>2020</b> , 7, 749-761   | 23.3 | 25  |
| 201 | Safety and effectiveness of lurasidone in adolescents with schizophrenia: results of a 2-year, open-label extension study. <i>CNS Spectrums</i> , <b>2020</b> , 1-11   | 1.8  | 6   |
| 200 | How mental health care should change as a consequence of the COVID-19 pandemic. <i>Lancet Psychiatry, the</i> , <b>2020</b> , 7, 813-824   | 23.3 | 542 |
| 199 | Safety of psychotropic medications in people with COVID-19: evidence review and practical recommendations. <i>BMC Medicine</i> , <b>2020</b> , 18, 215   | 11.4 | 30  |
| 198 | Universal and selective interventions to promote good mental health in young people: Systematic review and meta-analysis. <i>European Neuropsychopharmacology</i> , <b>2020</b> , 41, 28-39  | 1.2  | 25  |
| 197 | Pharmacological Management of Glucose Dysregulation in Patients Treated with Second-Generation Antipsychotics. <i>Drugs</i> , <b>2020</b> , 80, 1763-1781  | 12.1 | 10  |
| 196 | Impact of age and CYP2D6 genetics on exposure of aripiprazole and dehydroaripiprazole in patients using long-acting injectable versus oral formulation: relevance of poor and intermediate metabolizer status. <i>European Journal of Clinical Pharmacology</i> , <b>2020</b> , 76, 41-49  | 2.8  | 6   |
| 195 | Keeping up with the therapeutic advances in schizophrenia: a review of novel and emerging pharmacological entities. <i>CNS Spectrums</i> , <b>2019</b> , 24, 38-69   | 1.8  | 51  |
| 194 | An open-label randomised comparison of aripiprazole, olanzapine and risperidone for the acute treatment of first-episode schizophrenia: Eight-week outcomes. <i>Journal of Psychopharmacology</i> , <b>2019</b> , 33, 1227-1236  | 4.6  | 13  |
| 193 | Lifestyle Interventions for Weight Management in People with Serious Mental Illness: A Systematic Review with Meta-Analysis, Trial Sequential Analysis, and Meta-Regression Analysis Exploring the Mediators and Moderators of Treatment Effects. <i>Psychotherapy and Psychosomatics</i> , <b>2019</b> , 88, 350-362  | 9.4  | 26  |
| 192 | Association of Antidepressant Use With Adverse Health Outcomes: A Systematic Umbrella Review. <i>JAMA Psychiatry</i> , <b>2019</b> , 76, 1241-1255   | 14.5 | 72  |
| 191 | Abnormal involuntary movement scale in tardive dyskinesia: Minimal clinically important difference. <i>Movement Disorders</i> , <b>2019</b> , 34, 1203-1209  | 7    | 7   |
| 190 | Cardiometabolic Adverse Effects and Its Predictors in Children and Adolescents With First-Episode Psychosis During Treatment With Quetiapine-Extended Release Versus Aripiprazole: 12-Week Results From the Tolerance and Effect of Antipsychotics in Children and Adolescents With Psychosis (TEA) Trial. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , <b>2019</b> , 58, 1062-1078 | 7.2  | 10  |
| 189 | Trends in utilization and dosing of antipsychotic drugs in Scandinavia: Comparison of 2006 and 2016. <i>British Journal of Clinical Pharmacology</i> , <b>2019</b> , 85, 1598-1606   | 3.8  | 16  |
| 188 | Association With Hospitalization and All-Cause Discontinuation Among Patients With Schizophrenia on Clozapine vs Other Oral Second-Generation Antipsychotics: A Systematic Review and Meta-analysis of Cohort Studies. <i>JAMA Psychiatry</i> , <b>2019</b> , 76, 1052-1062  | 14.5 | 111 |
| 187 | The Lancet Psychiatry Commission: a blueprint for protecting physical health in people with mental illness. <i>Lancet Psychiatry, the</i> , <b>2019</b> , 6, 675-712   | 23.3 | 411 |
| 186 | Patient characteristics, burden and pharmacotherapy of treatment-resistant schizophrenia: results from a survey of 204 US psychiatrists. <i>BMC Psychiatry</i> , <b>2019</b> , 19, 362   | 4.2  | 12  |
| 185 | Association of Antipsychotic Polypharmacy vs Monotherapy With Psychiatric Rehospitalization Among Adults With Schizophrenia. <i>JAMA Psychiatry</i> , <b>2019</b> , 76, 499-507  | 14.5 | 106 |

|     |   |      |     |
|-----|---|------|-----|
| 184 | Exploration of Treatment-Resistant Schizophrenia Subtypes Based on a Survey of 204 US Psychiatrists. <i>Neuropsychiatric Disease and Treatment</i> , <b>2019</b> , 15, 3461-3473  | 3.1  | 5   |
| 183 | Clinical Guidance on the Identification and Management of Treatment-Resistant Schizophrenia. <i>Journal of Clinical Psychiatry</i> , <b>2019</b> , 80,  | 4.6  | 66  |
| 182 | Long-Acting Injections in Schizophrenia: a 3-Year Update on Randomized Controlled Trials Published January 2016-March 2019. <i>Current Psychiatry Reports</i> , <b>2019</b> , 21, 124   | 9.1  | 9   |
| 181 | Glucagon-like peptide-1 receptor agonists for antipsychotic-associated cardio-metabolic risk factors: A systematic review and individual participant data meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , <b>2019</b> , 21, 293-302  | 6.7  | 40  |
| 180 | The impact of pharmacological and non-pharmacological interventions to improve physical health outcomes in people with schizophrenia: a meta-review of meta-analyses of randomized controlled trials. <i>World Psychiatry</i> , <b>2019</b> , 18, 53-66   | 14.4 | 85  |
| 179 | High prevalence of prediabetes and metabolic abnormalities in overweight or obese schizophrenia patients treated with clozapine or olanzapine. <i>CNS Spectrums</i> , <b>2019</b> , 24, 441-452   | 1.8  | 8   |
| 178 | Practical considerations for managing breakthrough psychosis and symptomatic worsening in patients with schizophrenia on long-acting injectable antipsychotics. <i>CNS Spectrums</i> , <b>2019</b> , 24, 354-370  | 1.8  | 10  |
| 177 | Clozapine and Long-Term Mortality Risk in Patients With Schizophrenia: A Systematic Review and Meta-analysis of Studies Lasting 1.1-12.5 Years. <i>Schizophrenia Bulletin</i> , <b>2019</b> , 45, 315-329   | 1.3  | 87  |
| 176 | Network analysis of the relationship between depressive symptoms, demographics, nutrition, quality of life and medical condition factors in the Osteoarthritis Initiative database cohort of elderly North-American adults with or at risk for osteoarthritis. <i>Epidemiology and Psychiatric Sciences</i> , <b>2019</b> , 29, e14 | 5.1  | 6   |
| 175 | Clinical risk factors for the development of tardive dyskinesia. <i>Journal of the Neurological Sciences</i> , <b>2018</b> , 389, 21-27   | 3.2  | 64  |
| 174 | National Patterns of Commonly Prescribed Psychotropic Medications to Young People. <i>Journal of Child and Adolescent Psychopharmacology</i> , <b>2018</b> , 28, 158-165  | 2.9  | 29  |
| 173 | The pharmacological management of metabolic syndrome. <i>Expert Review of Clinical Pharmacology</i> , <b>2018</b> , 11, 397-410   | 3.8  | 56  |
| 172 | Comparison of Early Intervention Services vs Treatment as Usual for Early-Phase Psychosis: A Systematic Review, Meta-analysis, and Meta-regression. <i>JAMA Psychiatry</i> , <b>2018</b> , 75, 555-565  | 14.5 | 293 |
| 171 | The Validity and Sensitivity of PANSS-6 in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Study. <i>Schizophrenia Bulletin</i> , <b>2018</b> , 44, 453-462   | 1.3  | 14  |
| 170 | Psychopharmacological Treatment in the RAISE-ETP Study: Outcomes of a Manual and Computer Decision Support System Based Intervention. <i>American Journal of Psychiatry</i> , <b>2018</b> , 175, 169-179  | 11.9 | 30  |
| 169 | ECT augmentation of clozapine for clozapine-resistant schizophrenia: A meta-analysis of randomized controlled trials. <i>Journal of Psychiatric Research</i> , <b>2018</b> , 105, 23-32   | 5.2  | 42  |
| 168 | Impact of comprehensive treatment for first episode psychosis on substance use outcomes: A randomized controlled trial. <i>Psychiatry Research</i> , <b>2018</b> , 268, 303-311   | 9.9  | 28  |
| 167 | Clozapine and long-acting injectable antipsychotics reduce hospitalisation and treatment failure risk in patients with schizophrenia. <i>Evidence-Based Mental Health</i> , <b>2018</b> , 21, e11   | 11.1 |     |



|     |  |      |      |
|-----|--|------|------|
| 166 | Initiating/maintaining long-acting injectable antipsychotics in schizophrenia/schizoaffective or bipolar disorder - expert consensus survey part 2. <i>Neuropsychiatric Disease and Treatment</i> , <b>2018</b> , 14, 1475-1492 <sup>14</sup>  | 3.1  | 1492 |
| 165 | Antipsychotic Medication Treatment Patterns in Adult Depression. <i>Journal of Clinical Psychiatry</i> , <b>2018</b> , 79,   | 4.6  | 11   |
| 164 | A randomized, double-blind, placebo-controlled proof of concept study to evaluate samidorphan in the prevention of olanzapine-induced weight gain in healthy volunteers. <i>Schizophrenia Research</i> , <b>2018</b> , 195, 245-251  | 3.6  | 28   |
| 163 | Change and dispersion of QT interval during treatment with quetiapine extended release versus aripiprazole in children and adolescents with first-episode psychosis: results from the TEA trial. <i>Psychopharmacology</i> , <b>2018</b> , 235, 681-693  | 4.7  | 4    |
| 162 | Comorbidity of chronic somatic diseases in patients with psychotic disorders and their influence on 4-year outcomes of integrated care treatment (ACCESS II study). <i>Schizophrenia Research</i> , <b>2018</b> , 193, 377-383   | 3.6  | 11   |
| 161 | EPA guidance on physical activity as a treatment for severe mental illness: a meta-review of the evidence and Position Statement from the European Psychiatric Association (EPA), supported by the International Organization of Physical Therapists in Mental Health (IOPTMH). <i>European Psychiatry</i> , <b>2018</b> , 51, 124-134 | 6    | 197  |
| 160 | Sex and body weight are major determinants of venlafaxine pharmacokinetics. <i>International Clinical Psychopharmacology</i> , <b>2018</b> , 33, 322-329   | 2.2  | 7    |
| 159 | The acute efficacy of antipsychotics in schizophrenia: a review of recent meta-analyses. <i>Therapeutic Advances in Psychopharmacology</i> , <b>2018</b> , 8, 303-318  | 4.9  | 76   |
| 158 | Tardive dyskinesia risk with first- and second-generation antipsychotics in comparative randomized controlled trials: a meta-analysis. <i>World Psychiatry</i> , <b>2018</b> , 17, 330-340   | 14.4 | 73   |
| 157 | Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trials. <i>Drug Design, Development and Therapy</i> , <b>2018</b> , 12, 1215-1238   | 4.4  | 36   |
| 156 | Age Impacts Olanzapine Exposure Differently During Use of Oral Versus Long-Acting Injectable Formulations: An Observational Study Including 8,288 Patients. <i>Journal of Clinical Psychopharmacology</i> , <b>2018</b> , 38, 570-576  | 1.7  | 12   |
| 155 | What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia?. <i>World Psychiatry</i> , <b>2018</b> , 17, 149-160   | 14.4 | 116  |
| 154 | Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis. <i>World Psychiatry</i> , <b>2017</b> , 16, 77-89  | 14.4 | 109  |
| 153 | Reduced all-cause mortality with antipsychotics and antidepressants compared to increased all-cause mortality with benzodiazepines in patients with schizophrenia observed in naturalistic treatment settings. <i>Evidence-Based Mental Health</i> , <b>2017</b> , 20, e6  | 11.1 | 5    |
| 152 | Impairment in Social Functioning differentiates youth meeting Ultra-High Risk for psychosis criteria from other mental health help-seekers: A validation of the Italian version of the Global Functioning: Social and Global Functioning: Role scales. <i>Psychiatry Research</i> , <b>2017</b> , 253, 296-302                         | 9.9  | 9    |
| 151 | Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls. <i>World Psychiatry</i> , <b>2017</b> , 16, 163-180  | 14.4 | 688  |
| 150 | A Severity-Based Clinical Staging Model for the Psychosis Prodrome: Longitudinal Findings From the New York Recognition and Prevention Program. <i>Schizophrenia Bulletin</i> , <b>2017</b> , 43, 64-74  | 1.3  | 38   |
| 149 | Efficacy of 42 Pharmacologic Cotreatment Strategies Added to Antipsychotic Monotherapy in Schizophrenia: Systematic Overview and Quality Appraisal of the Meta-analytic Evidence. <i>JAMA Psychiatry</i> , <b>2017</b> , 74, 675-684   | 14.5 | 94   |

|     |  |      |     |
|-----|--|------|-----|
| 148 | Atypical antipsychotics: recent research findings and applications to clinical practice: Proceedings of a symposium presented at the 29th Annual European College of Neuropsychopharmacology Congress, 19 September 2016, Vienna, Austria. <i>Therapeutic Advances in Psychopharmacology</i> , <b>2017</b> , 7, 1-14 | 4.9  | 14  |
| 147 | Cardiometabolic comorbidities, readmission, and costs in schizophrenia and bipolar disorder: a real-world analysis. <i>Annals of General Psychiatry</i> , <b>2017</b> , 16, 9  | 3.4  | 33  |
| 146 | Psychological well-being and mental health recovery in the NIMH RAISE early treatment program. <i>Schizophrenia Research</i> , <b>2017</b> , 185, 167-172  | 3.6  | 15  |
| 145 | Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology. <i>American Journal of Psychiatry</i> , <b>2017</b> , 174, 216-229  | 11.9 | 408 |
| 144 | Oral Aripiprazole as Maintenance Treatment in Adolescent Schizophrenia: Results From a 52-Week, Randomized, Placebo-Controlled Withdrawal Study. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , <b>2017</b> , 56, 784-792   | 7.2  | 17  |
| 143 | A new class of VMAT-2 inhibitors for tardive dyskinesia. <i>Lancet Psychiatry</i> , <b>2017</b> , 4, 574-575   | 23.3 | 3   |
| 142 | Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review. <i>Therapeutics and Clinical Risk Management</i> , <b>2017</b> , 13, 757-777  | 2.9  | 194 |
| 141 | Comprehensive Versus Usual Community Care for First-Episode Psychosis: 2-Year Outcomes From the NIMH RAISE Early Treatment Program. <i>American Journal of Psychiatry</i> , <b>2016</b> , 173, 362-72  | 11.9 | 431 |
| 140 | Physical multimorbidity and psychosis: comprehensive cross sectional analysis including 242,952 people across 48 low- and middle-income countries. <i>BMC Medicine</i> , <b>2016</b> , 14, 189   | 11.4 | 84  |
| 139 | Duration of attenuated positive and negative symptoms in individuals at clinical high risk: Associations with risk of conversion to psychosis and functional outcome. <i>Journal of Psychiatric Research</i> , <b>2016</b> , 81, 95-101  | 5.2  | 49  |
| 138 | Activating and Tranquilizing Effects of First-Time Treatment with Aripiprazole, Olanzapine, Quetiapine, and Risperidone in Youth. <i>Journal of Child and Adolescent Psychopharmacology</i> , <b>2016</b> , 26, 458-70   | 2.9  | 14  |
| 137 | Self-Reported and Interviewer-Rated Oral Health in Patients With Schizophrenia, Bipolar Disorder, and Major Depressive Disorder. <i>Perspectives in Psychiatric Care</i> , <b>2016</b> , 52, 4-11  | 2.2  | 12  |
| 136 | The Role of Clozapine in Treatment-Resistant Schizophrenia. <i>JAMA Psychiatry</i> , <b>2016</b> , 73, 187-8   | 14.5 | 53  |
| 135 | Safety and tolerability of antipsychotic co-treatment in patients with schizophrenia: results from a systematic review and meta-analysis of randomized controlled trials. <i>Expert Opinion on Drug Safety</i> , <b>2016</b> , 15, 591-612   | 4.1  | 24  |
| 134 | Attenuated psychotic and basic symptom characteristics in adolescents with ultra-high risk criteria for psychosis, other non-psychotic psychiatric disorders and early-onset psychosis. <i>European Child and Adolescent Psychiatry</i> , <b>2016</b> , 25, 1091-102   | 5.5  | 24  |
| 133 | The association between smoking prevalence and eating disorders: a systematic review and meta-analysis. <i>Addiction</i> , <b>2016</b> , 111, 1914-1922  | 4.6  | 47  |
| 132 | Digital Parent Training for Children with Disruptive Behaviors: Systematic Review and Meta-Analysis of Randomized Trials. <i>Journal of Child and Adolescent Psychopharmacology</i> , <b>2016</b> , 26, 740-749  | 2.8  | 43  |
| 131 | Pharmacogenetic Associations of Antipsychotic Drug-Related Weight Gain: A Systematic Review and Meta-analysis. <i>Schizophrenia Bulletin</i> , <b>2016</b> , 42, 1418-1437   | 1.3  | 103 |



|     |   |      |     |
|-----|---|------|-----|
| 130 | ITI-007 in the treatment of schizophrenia: from novel pharmacology to clinical outcomes. <i>Expert Review of Neurotherapeutics</i> , <b>2016</b> , 16, 601-14   | 4.3  | 26  |
| 129 | Antipsychotic Use Trends in Youth With Autism Spectrum Disorder and/or Intellectual Disability: A Meta-Analysis. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , <b>2016</b> , 55, 456-468.e4   | 7.2  | 46  |
| 128 | Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a systematic review and large scale meta-analysis. <i>World Psychiatry</i> , <b>2016</b> , 15, 166-74   | 14.4 | 365 |
| 127 | Neuromotor Adverse Effects in 342 Youth During 12 Weeks of Naturalistic Treatment With 5 Second-Generation Antipsychotics. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , <b>2015</b> , 54, 718-727.e3   | 7.2  | 26  |
| 126 | Unmet needs in paediatric psychopharmacology: Present scenario and future perspectives. <i>European Neuropsychopharmacology</i> , <b>2015</b> , 25, 1513-31   | 1.2  | 37  |
| 125 | Frequency and correlates of antipsychotic polypharmacy among patients with schizophrenia in Denmark: A nation-wide pharmacoepidemiological study. <i>European Neuropsychopharmacology</i> , <b>2015</b> , 25, 1669-76   | 1.2  | 19  |
| 124 | Child and adolescent psychiatrists reported monitoring behaviors for second-generation antipsychotics. <i>Journal of Child and Adolescent Psychopharmacology</i> , <b>2015</b> , 25, 351-61   | 2.9  | 27  |
| 123 | Antipsychotic polypharmacy in schizophrenia patients in China and its association with treatment satisfaction and quality of life: findings of the third national survey on use of psychotropic medications in China. <i>Australian and New Zealand Journal of Psychiatry</i> , <b>2015</b> , 49, 129-36    | 2.6  | 34  |
| 122 | Duration of Untreated Psychosis in Community Treatment Settings in the United States. <i>Psychiatric Services</i> , <b>2015</b> , 66, 753-6   | 3.3  | 80  |
| 121 | Outcome of Youth with Early-Phase Schizophrenia-Spectrum Disorders and Psychosis Not Otherwise Specified Treated with Second-Generation Antipsychotics: 12 Week Results from a Prospective, Naturalistic Cohort Study. <i>Journal of Child and Adolescent Psychopharmacology</i> , <b>2015</b> , 25, 525-47 | 2.9  | 6   |
| 120 | A Randomized Comparison of Aripiprazole and Risperidone for the Acute Treatment of First-Episode Schizophrenia and Related Disorders: 3-Month Outcomes. <i>Schizophrenia Bulletin</i> , <b>2015</b> , 41, 1227-36   | 1.3  | 78  |
| 119 | Clozapine in schizophrenia and its association with treatment satisfaction and quality of life: Findings of the three national surveys on use of psychotropic medications in China (2002-2012). <i>Schizophrenia Research</i> , <b>2015</b> , 168, 523-9  | 3.6  | 13  |
| 118 | Lack of cardinal symptoms of meningitis in a hospitalized patient with chronic schizophrenia: lessons to be learned. <i>General Hospital Psychiatry</i> , <b>2015</b> , 37, 621.e3-4  | 5.6  | 2   |
| 117 | Do antipsychotics increase diabetes risk in children and adolescents?. <i>Expert Opinion on Drug Safety</i> , <b>2015</b> , 14, 219-41  | 4.1  | 21  |
| 116 | Corrected QT changes during antipsychotic treatment of children and adolescents: a systematic review and meta-analysis of clinical trials. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , <b>2015</b> , 54, 25-36  | 7.2  | 46  |
| 115 | Prescription practices in the treatment of first-episode schizophrenia spectrum disorders: data from the national RAISE-ETP study. <i>American Journal of Psychiatry</i> , <b>2015</b> , 172, 237-48  | 11.9 | 61  |
| 114 | Cardiovascular and cerebrovascular risk factors and events associated with second-generation antipsychotic compared to antidepressant use in a non-elderly adult sample: results from a claims-based inception cohort study. <i>World Psychiatry</i> , <b>2015</b> , 14, 56-63                              | 14.4 | 71  |
| 113 | Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. <i>World Psychiatry</i> , <b>2015</b> , 14, 119-36   | 14.4 | 432 |

|     |   |      |     |
|-----|---|------|-----|
| 112 | Schizophrenia. <i>Nature Reviews Disease Primers</i> , <b>2015</b> , 1, 15067   | 51.1 | 432 |
| 111 | Decreased pain sensitivity among people with schizophrenia: a meta-analysis of experimental pain induction studies. <i>Pain</i> , <b>2015</b> , 156, 2121-2131  | 8    | 74  |
| 110 | Psychosis Prevention: A Modified Clinical High Risk Perspective From the Recognition and Prevention (RAP) Program. <i>American Journal of Psychiatry</i> , <b>2015</b> , 172, 986-94  | 11.9 | 109 |
| 109 | Early Improvement As a Predictor of Later Response to Antipsychotics in Schizophrenia: A Diagnostic Test Review. <i>American Journal of Psychiatry</i> , <b>2015</b> , 172, 617-29  | 11.9 | 111 |
| 108 | Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis. <i>World Psychiatry</i> , <b>2015</b> , 14, 339-47                                     | 14.4 | 627 |
| 107 | The RAISE early treatment program for first-episode psychosis: background, rationale, and study design. <i>Journal of Clinical Psychiatry</i> , <b>2015</b> , 76, 240-6   | 4.6  | 86  |
| 106 | Elevated blood urea nitrogen and medical outcome of psychiatric inpatients. <i>Psychiatric Quarterly</i> , <b>2014</b> , 85, 111-20   | 4.1  | 1   |
| 105 | Second-generation antipsychotic use in children and adolescents: a six-month prospective cohort study in drug-naïve patients. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , <b>2014</b> , 53, 1179-90, 1190.e1-4  | 7.2  | 60  |
| 104 | Emerging drugs for schizophrenia: an update. <i>Expert Opinion on Emerging Drugs</i> , <b>2014</b> , 19, 511-31   | 3.7  | 38  |
| 103 | SENTIA: a systematic online monitoring registry for children and adolescents treated with antipsychotics. <i>SpringerPlus</i> , <b>2014</b> , 3, 187  |      | 10  |
| 102 | BDNF Val66Met polymorphism and antipsychotic-induced tardive dyskinesia occurrence and severity: a meta-analysis. <i>Schizophrenia Research</i> , <b>2014</b> , 152, 365-72   | 3.6  | 18  |
| 101 | Risk of diabetes in children and adolescents exposed to antipsychotics: a nationwide 12-year case-control study. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , <b>2014</b> , 53, 971-979.e6   | 7.2  | 18  |
| 100 | Sudden unexpected death in schizophrenia: autopsy findings in psychiatric inpatients. <i>Schizophrenia Research</i> , <b>2014</b> , 155, 72-6   | 3.6  | 56  |
| 99  | Type and duration of subsyndromal symptoms in youth with bipolar I disorder prior to their first manic episode. <i>Bipolar Disorders</i> , <b>2014</b> , 16, 478-92   | 3.8  | 68  |
| 98  | Prevalence and correlates of antipsychotic polypharmacy in children and adolescents receiving antipsychotic treatment. <i>International Journal of Neuropsychopharmacology</i> , <b>2014</b> , 17, 1095-105   | 5.8  | 35  |
| 97  | Diabetes risk potentially underestimated in youth and children receiving antipsychotics. <i>JAMA Psychiatry</i> , <b>2014</b> , 71, 209-10  | 14.5 | 13  |
| 96  | Can an early weight management program (WMP) prevent olanzapine (OLZ)-induced disturbances in body weight, blood glucose and lipid metabolism? Twenty-four- and 48-week results from a 6-month randomized trial. <i>World Journal of Biological Psychiatry</i> , <b>2014</b> , 15, 229-41 | 3.8  | 15  |
| 95  | Does a GLP-1 receptor agonist change glucose tolerance in patients treated with antipsychotic medications? Design of a randomised, double-blinded, placebo-controlled clinical trial. <i>BMJ Open</i> , <b>2014</b> , 4, e004227  | 3    | 13  |

|    |  |      |     |
|----|--|------|-----|
| 94 | Adherence to guidelines for glucose assessment in starting second-generation antipsychotics. <i>Pediatrics</i> , <b>2014</b> , 134, e1308-14   | 7.4  | 29  |
| 93 | Common use of high doses of antipsychotic medications in older Asian patients with schizophrenia (2001-2009). <i>International Journal of Geriatric Psychiatry</i> , <b>2014</b> , 29, 359-66  | 3.9  | 15  |
| 92 | The prevalence and moderators of clinical pain in people with schizophrenia: a systematic review and large scale meta-analysis. <i>Schizophrenia Research</i> , <b>2014</b> , 160, 1-8   | 3.6  | 55  |
| 91 | National trends in the mental health care of children, adolescents, and adults by office-based physicians. <i>JAMA Psychiatry</i> , <b>2014</b> , 71, 81-90  | 14.5 | 292 |
| 90 | Quetiapine versus aripiprazole in children and adolescents with psychosis--protocol for the randomised, blinded clinical Tolerability and Efficacy of Antipsychotics (TEA) trial. <i>BMC Psychiatry</i> , <b>2014</b> , 14, 199                | 4.2  | 10  |
| 89 | Cardiometabolic risk in patients with first-episode schizophrenia spectrum disorders: baseline results from the RAISE-ETP study. <i>JAMA Psychiatry</i> , <b>2014</b> , 71, 1350-63  | 14.5 | 254 |
| 88 | National trends in second-generation antipsychotic augmentation for nonpsychotic depression. <i>Journal of Clinical Psychiatry</i> , <b>2014</b> , 75, 490-7   | 4.6  | 30  |
| 87 | Body mass index identified as an independent predictor of psychiatric readmission. <i>Journal of Clinical Psychiatry</i> , <b>2014</b> , 75, e573-7  | 4.6  | 24  |
| 86 | Pharmacoepidemiology of antipsychotic use in youth with ADHD: trends and clinical implications. <i>Current Psychiatry Reports</i> , <b>2013</b> , 15, 382  | 9.1  | 26  |
| 85 | Improving metabolic parameters of antipsychotic child treatment (IMPACT) study: rationale, design, and methods. <i>Child and Adolescent Psychiatry and Mental Health</i> , <b>2013</b> , 7, 31   | 6.8  | 18  |
| 84 | Antipsychotic polypharmacy: a Japanese survey of prescribers' attitudes and rationales. <i>Psychiatry Research</i> , <b>2013</b> , 209, 406-11   | 9.9  | 18  |
| 83 | Early antipsychotic response to aripiprazole in adolescents with schizophrenia: predictive value for clinical outcomes. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , <b>2013</b> , 52, 689-698                  | 7.3  | 16  |
| 82 | Aripiprazole for the treatment of pediatric bipolar I disorder: a 30-week, randomized, placebo-controlled study. <i>Bipolar Disorders</i> , <b>2013</b> , 15, 138-49   | 3.8  | 51  |
| 81 | Prevalence of the metabolic syndrome in patients with borderline personality disorder: results from a cross-sectional study. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , <b>2013</b> , 263, 205-13                      | 5.1  | 41  |
| 80 | Associations among obesity, acute weight gain, and response to treatment with olanzapine in adolescent schizophrenia. <i>Journal of Child and Adolescent Psychopharmacology</i> , <b>2013</b> , 23, 522-30                                     | 2.9  | 26  |
| 79 | Adjunctive use of nonsteroidal anti-inflammatory drugs for schizophrenia: a meta-analytic investigation of randomized controlled trials. <i>Schizophrenia Bulletin</i> , <b>2013</b> , 39, 1230-41   | 1.3  | 133 |
| 78 | Response to Bartoli et al. <i>American Journal of Psychiatry</i> , <b>2013</b> , 170, 928-9  | 11.9 | 2   |
| 77 | Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis. <i>International Journal of Neuropsychopharmacology</i> , <b>2013</b> , 16, 1205-18 | 5.8  | 186 |

|    |  |      |     |
|----|--|------|-----|
| 76 | Prediction of functional outcome in individuals at clinical high risk for psychosis. <i>JAMA Psychiatry</i> , <b>2013</b> , 70, 1133-42  | 14.5 | 162 |
| 75 | Antipsychotic polypharmacy in a treatment-refractory schizophrenia population receiving adjunctive treatment with electroconvulsive therapy. <i>Journal of ECT</i> , <b>2013</b> , 29, 271-6   | 2    | 15  |
| 74 | CNR1 gene and risk of the metabolic syndrome in patients with schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , <b>2013</b> , 33, 186-92  | 1.7  | 23  |
| 73 | Treatment of adolescents with early-onset schizophrenia spectrum disorders: in search of a rational, evidence-informed approach. <i>Current Opinion in Psychiatry</i> , <b>2013</b> , 26, 219-30   | 4.9  | 62  |
| 72 | A meta-analysis of cardio-metabolic abnormalities in drug naïve, first-episode and multi-episode patients with schizophrenia versus general population controls. <i>World Psychiatry</i> , <b>2013</b> , 12, 240-50  | 14.4 | 168 |
| 71 | Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies. <i>World Psychiatry</i> , <b>2013</b> , 12, 216-26   | 14.4 | 256 |
| 70 | Metabolic syndrome and metabolic abnormalities in bipolar disorder: a meta-analysis of prevalence rates and moderators. <i>American Journal of Psychiatry</i> , <b>2013</b> , 170, 265-74  | 11.9 | 272 |
| 69 | Prescribing of psychotropic medications to children and adolescents: quo vadis?. <i>World Psychiatry</i> , <b>2013</b> , 12, 127-8   | 14.4 | 7   |
| 68 | Early nonresponse determined by the clinical global impressions scale predicts poorer outcomes in youth with schizophrenia spectrum disorders naturalistically treated with second-generation antipsychotics. <i>Journal of Child and Adolescent Psychopharmacology</i> , <b>2013</b> , 23, 665-75 | 2.9  | 25  |
| 67 | Termination of clozapine treatment due to medical reasons: when is it warranted and how can it be avoided?. <i>Journal of Clinical Psychiatry</i> , <b>2013</b> , 74, 603-13; quiz 613   | 4.6  | 148 |
| 66 | Pediatric Schizophrenia <b>2013</b> , 1-6  |      |     |
| 65 | Association between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug-induced weight gain. <i>Archives of General Psychiatry</i> , <b>2012</b> , 69, 904-12  |      | 142 |
| 64 | Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis. <i>CNS Drugs</i> , <b>2012</b> , 26, 733-59  | 6.7  | 113 |
| 63 | Safety and tolerability of antipsychotic polypharmacy. <i>Expert Opinion on Drug Safety</i> , <b>2012</b> , 11, 527-42   | 4.1  | 130 |
| 62 | When can patients with potentially life-threatening adverse effects be rechallenged with clozapine? A systematic review of the published literature. <i>Schizophrenia Research</i> , <b>2012</b> , 134, 180-6  | 3.6  | 104 |
| 61 | Acute and maintenance effects of non-pharmacologic interventions for antipsychotic associated weight gain and metabolic abnormalities: a meta-analytic comparison of randomized controlled trials. <i>Schizophrenia Research</i> , <b>2012</b> , 140, 159-68                                       | 3.6  | 129 |
| 60 | Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009. <i>Schizophrenia Research</i> , <b>2012</b> , 138, 18-28  | 3.6  | 196 |
| 59 | Antipsychotic polypharmacy: a comprehensive evaluation of relevant correlates of a long-standing clinical practice. <i>Psychiatric Clinics of North America</i> , <b>2012</b> , 35, 661-81   | 3.1  | 78  |

|    |   |      |      |
|----|---|------|------|
| 58 | Recent advances in understanding and mitigating adipogenic and metabolic effects of antipsychotic drugs. <i>Frontiers in Psychiatry</i> , <b>2012</b> , 3, 62   | 5    | 19   |
| 57 | Are antipsychotics or antidepressants needed for psychotic depression? A systematic review and meta-analysis of trials comparing antidepressant or antipsychotic monotherapy with combination treatment. <i>Journal of Clinical Psychiatry</i> , <b>2012</b> , 73, 486-96   | 4.6  | 79   |
| 56 | Treatment of maladaptive aggression in youth: CERT guidelines II. Treatments and ongoing management. <i>Pediatrics</i> , <b>2012</b> , 129, e1577-86  | 7.4  | 89   |
| 55 | Osteoporosis and fracture risk in people with schizophrenia. <i>Current Opinion in Psychiatry</i> , <b>2012</b> , 25, 415-20  | 4.9  | 74   |
| 54 | Effectiveness of a cognitive behavioral weight management intervention in obese patients with psychotic disorders compared to patients with nonpsychotic disorders or no psychiatric disorders: results from a 12-month, real-world study. <i>Journal of Clinical Psychopharmacology</i> , <b>2012</b> , 32, 458-64 | 1.7  | 11   |
| 53 | Differences in body mass index z-scores and weight status in a Dutch pediatric psychiatric population with and without use of second-generation antipsychotics. <i>Journal of Child and Adolescent Psychopharmacology</i> , <b>2012</b> , 22, 166-73  | 2.9  | 15   |
| 52 | Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. <i>Nature Reviews Endocrinology</i> , <b>2011</b> , 8, 114-26   | 15.2 | 633  |
| 51 | Weight gain and metabolic risks associated with antipsychotic medications in children and adolescents. <i>Journal of Child and Adolescent Psychopharmacology</i> , <b>2011</b> , 21, 517-35   | 2.9  | 184  |
| 50 | Antipsychotic polypharmacy: a survey study of prescriber attitudes, knowledge and behavior. <i>Schizophrenia Research</i> , <b>2011</b> , 131, 58-62  | 3.6  | 64   |
| 49 | Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level. <i>World Psychiatry</i> , <b>2011</b> , 10, 138-51   | 14.4 | 489  |
| 48 | Antipsychotic drugs and obesity. <i>Trends in Molecular Medicine</i> , <b>2011</b> , 17, 97-107   | 11.5 | 202  |
| 47 | Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: comprehensive review of prospective head-to-head and placebo-controlled comparisons. <i>European Neuropsychopharmacology</i> , <b>2011</b> , 21, 621-45                          | 1.2  | 142  |
| 46 | Incidence of tardive dyskinesia with risperidone or olanzapine in the elderly: results from a 2-year, prospective study in antipsychotic-naïve patients. <i>Neuropsychopharmacology</i> , <b>2011</b> , 36, 1738-46   | 8.7  | 38   |
| 45 | Quantifying clinical relevance in the treatment of schizophrenia. <i>Clinical Therapeutics</i> , <b>2011</b> , 33, B16-39   | 3.5  | 73   |
| 44 | Obesity and coronary risk in patients treated with second-generation antipsychotics. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , <b>2011</b> , 261, 417-23   | 5.1  | 24   |
| 43 | Antipsychotic drug administration does not correlate with prolonged rate-corrected QT interval in children and adolescents: results from a nested case-control study. <i>Journal of Child and Adolescent Psychopharmacology</i> , <b>2011</b> , 21, 365-8   | 2.9  | 24   |
| 42 | Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. <i>World Psychiatry</i> , <b>2011</b> , 10, 52-77   | 14.4 | 1288 |
| 41 | Randomized controlled trials in schizophrenia: opportunities, limitations, and trial design alternatives. <i>Dialogues in Clinical Neuroscience</i> , <b>2011</b> , 13, 155-72  | 5.7  | 30   |



|    |  |      |     |
|----|--|------|-----|
| 40 | Determinants of poor dental care in patients with schizophrenia: a historical, prospective database study. <i>Journal of Clinical Psychiatry</i> , <b>2011</b> , 72, 140-3   | 4.6  | 44  |
| 39 | Research in people with psychosis risk syndrome: a review of the current evidence and future directions. <i>Journal of Child Psychology and Psychiatry and Allied Disciplines</i> , <b>2010</b> , 51, 390-431  | 7.9  | 136 |
| 38 | Antipsychotic and mood stabilizer efficacy and tolerability in pediatric and adult patients with bipolar I mania: a comparative analysis of acute, randomized, placebo-controlled trials. <i>Bipolar Disorders</i> , <b>2010</b> , 12, 116-41  | 3.8  | 143 |
| 37 | Past and present progress in the pharmacologic treatment of schizophrenia. <i>Journal of Clinical Psychiatry</i> , <b>2010</b> , 71, 1115-24   | 4.6  | 161 |
| 36 | Antipsychotics associated with the development of type 2 diabetes in antipsychotic-naïve schizophrenia patients. <i>Neuropsychopharmacology</i> , <b>2010</b> , 35, 1997-2004  | 8.7  | 158 |
| 35 | Do antipsychotic medications reduce or increase mortality in schizophrenia? A critical appraisal of the FIN-11 study. <i>Schizophrenia Research</i> , <b>2010</b> , 117, 68-74   | 3.6  | 78  |
| 34 | Management of antipsychotic-related weight gain. <i>Expert Review of Neurotherapeutics</i> , <b>2010</b> , 10, 1175-2009   | 4.0  | 77  |
| 33 | Switching and combining antipsychotics. <i>CNS Spectrums</i> , <b>2010</b> , 15, 8-11  | 1.8  | 5   |
| 32 | Pharmacologic treatment of schizophrenia. <i>Dialogues in Clinical Neuroscience</i> , <b>2010</b> , 12, 345-57   | 5.7  | 67  |
| 31 | Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. <i>Schizophrenia Bulletin</i> , <b>2009</b> , 35, 443-57  | 1.3  | 301 |
| 30 | Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. <i>JAMA - Journal of the American Medical Association</i> , <b>2009</b> , 302, 1765-73  | 27.4 | 699 |
| 29 | Second-generation antipsychotic-associated diabetes mellitus and diabetic ketoacidosis: mechanisms, predictors, and screening need. <i>Journal of Clinical Psychiatry</i> , <b>2009</b> , 70, 765-6  | 4.6  | 29  |
| 28 | Equally increased risk for metabolic syndrome in patients with bipolar disorder and schizophrenia treated with second-generation antipsychotics. <i>Bipolar Disorders</i> , <b>2008</b> , 10, 788-97   | 3.8  | 120 |
| 27 | Monitoring and management of antipsychotic-related metabolic and endocrine adverse events in pediatric patients. <i>International Review of Psychiatry</i> , <b>2008</b> , 20, 195-201   | 3.6  | 69  |
| 26 | Predictors of remission, schizophrenia, and bipolar disorder in adolescents with brief psychotic disorder or psychotic disorder not otherwise specified considered at very high risk for schizophrenia. <i>Journal of Child and Adolescent Psychopharmacology</i> , <b>2008</b> , 18, 475-90 | 2.9  | 45  |
| 25 | Antipsychotic use in children and adolescents: minimizing adverse effects to maximize outcomes. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , <b>2008</b> , 47, 9-20   | 7.2  | 201 |
| 24 | Side effects of second-generation antipsychotics: the experiences, views and monitoring practices of Australian child psychiatrists. <i>Australasian Psychiatry</i> , <b>2008</b> , 16, 253-62   | 1.7  | 33  |
| 23 | Antipsychotic Use in Children and Adolescents: Minimizing Adverse Effects to Maximize Outcomes. <i>Focus (American Psychiatric Publishing)</i> , <b>2008</b> , 6, 368-378  | 1.1  | 5   |



|    |   |      |     |
|----|---|------|-----|
| 22 | Tardive dyskinesia and new antipsychotics. <i>Current Opinion in Psychiatry</i> , <b>2008</b> , 21, 151-6   | 4.9  | 278 |
| 21 | Assessing and maximizing the safety and tolerability of antipsychotics used in the treatment of children and adolescents. <i>Journal of Clinical Psychiatry</i> , <b>2008</b> , 69 Suppl 4, 26-36                                   | 4.6  | 43  |
| 20 | Does antipsychotic polypharmacy increase the risk for metabolic syndrome?. <i>Schizophrenia Research</i> , <b>2007</b> , 89, 91-100   | 3.6  | 197 |
| 19 | First-episode psychosis: a window of opportunity for best practices. <i>CNS Spectrums</i> , <b>2007</b> , 12, 1-12; discussion 13-4; quiz 15-6  | 1.8  | 12  |
| 18 | Differentiation in the preonset phases of schizophrenia and mood disorders: evidence in support of a bipolar mania prodrome. <i>Schizophrenia Bulletin</i> , <b>2007</b> , 33, 703-14   | 1.3  | 135 |
| 17 | One-year incidence rates of tardive dyskinesia in children and adolescents treated with second-generation antipsychotics: a systematic review. <i>Journal of Child and Adolescent Psychopharmacology</i> , <b>2007</b> , 17, 647-56 | 2.9  | 64  |
| 16 | Acute and long-term adverse effects of antipsychotics. <i>CNS Spectrums</i> , <b>2007</b> , 12, 10-4  | 1.8  | 22  |
| 15 | Balancing efficacy and safety in treatment with antipsychotics. <i>CNS Spectrums</i> , <b>2007</b> , 12, 12-20, 35  | 1.8  | 56  |
| 14 | Pharmacological management of bipolar disorder in a youth with diabetes. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , <b>2007</b> , 46, 1375-1379  | 7.2  | 3   |
| 13 | Recognizing and monitoring adverse events of second-generation antipsychotics in children and adolescents. <i>Child and Adolescent Psychiatric Clinics of North America</i> , <b>2006</b> , 15, 177-206                             | 3.3  | 138 |
| 12 | Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , <b>2006</b> , 45, 771-91                               | 7.2  | 298 |
| 11 | Metabolic syndrome and the risk of coronary heart disease in 367 patients treated with second-generation antipsychotic drugs. <i>Journal of Clinical Psychiatry</i> , <b>2006</b> , 67, 575-83                                      | 4.6  | 148 |
| 10 | Prospective study of adolescents with subsyndromal psychosis: characteristics and outcome. <i>Journal of Child and Adolescent Psychopharmacology</i> , <b>2005</b> , 15, 418-33   | 2.9  | 31  |
| 9  | Cost-effective screening for the metabolic syndrome in patients treated with second-generation antipsychotic medications. <i>American Journal of Psychiatry</i> , <b>2005</b> , 162, 1217-21  | 11.9 | 78  |
| 8  | Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. <i>American Journal of Psychiatry</i> , <b>2004</b> , 161, 414-25  | 11.9 | 566 |
| 7  | Pharmacogenetics of antipsychotic-induced weight gain. <i>Psychopharmacology</i> , <b>2004</b> , 174, 477-89  | 4.7  | 71  |
| 6  | The schizophrenia prodrome revisited: a neurodevelopmental perspective. <i>Schizophrenia Bulletin</i> , <b>2003</b> , 29, 633-51  | 1.3  | 290 |
| 5  | The assessment of "prodromal schizophrenia": unresolved issues and future directions. <i>Schizophrenia Bulletin</i> , <b>2003</b> , 29, 717-28  | 1.3  | 62  |

|   |  |      |     |
|---|--|------|-----|
| 4 | Treatment models and designs for intervention research during the psychotic prodrome. <i>Schizophrenia Bulletin</i> , <b>2003</b> , 29, 747-56 | 1.3  | 15  |
| 3 | Early prediction of antipsychotic response in schizophrenia. <i>American Journal of Psychiatry</i> , <b>2003</b> , 160, 2063-5                 | 11.9 | 139 |
| 2 | Approaches to Treatment-Resistant Patients 540-560   |      | 1   |
| 1 | Drug-drug interactions involving antipsychotics and antihypertensives. <i>Expert Opinion on Drug Metabolism and Toxicology</i> ,               | 5.5  | 1   |